Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
- PMID: 17898045
- DOI: 10.1093/intimm/dxm091
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Abstract
Negative co-stimulatory signaling mediated via cell surface programmed death (PD)-1 expression modulates T and B cell activation and is involved in maintaining peripheral tolerance. In this study, we examined the effects of a fully human PD-1-abrogating antibody on the in vitro expansion and function of human vaccine-induced CD8+ T cells (CTLs) specific for the melanoma-associated antigens glycoprotein 100 (gp100) and melanoma antigen recognized by T cells (MART)-1. PD-1 blockade during peptide stimulation augmented the absolute numbers of CD3+, CD4+, CD8+ and gp100/MART-1 MHC:peptide tetramer+ CTLs. This correlated with increased frequencies of IFN-gamma-secreting antigen-specific cells and augmented lysis of gp100+/MART-1+ melanoma targets. PD-1 blockade also increased the fraction of antigen-specific CTLs that recognized melanoma targets by degranulation, suggesting increased recognition efficiency for cognate peptide. The increased frequencies and absolute numbers of antigen-specific CTLs by PD-1 blockade resulted from augmented proliferation, not decreased apoptosis. Kinetic analysis of cytokine secretion demonstrated that PD-1 blockade increased both type-1 and type-2 cytokine accumulation in culture without any apparent skewing of the cytokine repertoire. These findings have implications for developing new cancer immunotherapy strategies.
Similar articles
-
Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.Int J Oncol. 2008 Sep;33(3):433-41. Int J Oncol. 2008. PMID: 18695871
-
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.Cancer Res. 1995 Nov 1;55(21):4972-9. Cancer Res. 1995. PMID: 7585538
-
Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.J Immunol. 1996 Jan 15;156(2):700-10. J Immunol. 1996. PMID: 8543823
-
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Cancer Immunol Immunother. 2011. PMID: 21465316 Free PMC article. Review.
-
New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system.Cornea. 2000 May;19(3 Suppl):S2-6. doi: 10.1097/00003226-200005001-00002. Cornea. 2000. PMID: 10832714 Review.
Cited by
-
Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.Front Immunol. 2024 Oct 28;15:1454720. doi: 10.3389/fimmu.2024.1454720. eCollection 2024. Front Immunol. 2024. PMID: 39530091 Free PMC article. Review.
-
CTLA-4 expression on CD4+ lymphocytes in patients with sepsis-associated immunosuppression and its relationship to mTOR mediated autophagic-lysosomal disorder.Front Immunol. 2024 Jul 22;15:1396157. doi: 10.3389/fimmu.2024.1396157. eCollection 2024. Front Immunol. 2024. PMID: 39104530 Free PMC article.
-
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.J Hematol Oncol. 2024 Jul 27;17(1):54. doi: 10.1186/s13045-024-01581-2. J Hematol Oncol. 2024. PMID: 39068460 Free PMC article. Review.
-
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).Oncoimmunology. 2024 Jun 24;13(1):2371563. doi: 10.1080/2162402X.2024.2371563. eCollection 2024. Oncoimmunology. 2024. PMID: 38919826 Free PMC article. Clinical Trial.
-
Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China.Int J Clin Pharm. 2024 Apr;46(2):429-438. doi: 10.1007/s11096-023-01675-w. Epub 2024 Jan 2. Int J Clin Pharm. 2024. PMID: 38165516
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials